Group 1 - The core viewpoint of the news is that Baiaosaitu has successfully listed its H-shares on the Hong Kong Stock Exchange and has been included in the Hong Kong Stock Connect program, allowing eligible investors from mainland China to invest directly in its H-shares [1][3] - Following this announcement, Baiaosaitu's H-shares surged by 22.23% to HKD 35.08 per share, while its A-shares increased by 3.42% to CNY 52.6 per share, indicating strong market reaction [1] - The inclusion in the Hong Kong Stock Connect is seen as a significant milestone for the company, enhancing its capital accessibility, market recognition, and long-term investment value [1][3] Group 2 - Baiaosaitu, established in 2009, operates as a preclinical CRO and biopharmaceutical company, providing innovative animal models and preclinical drug development services based on its proprietary gene editing technology [2] - The company has developed a comprehensive platform for drug discovery and development, including the RenMice platform, which targets over a thousand potential drug targets [2] - Baiaosaitu has signed approximately 280 drug cooperation development, licensing, and transfer agreements, establishing a leading global repository of humanized mouse models and offering full-chain capabilities in preclinical pharmacology and efficacy research [3] Group 3 - The company aims to leverage the synergy between its A-share and H-share platforms to enhance its technological platform transformation, global business expansion, and long-term strategic implementation [3] - Baiaosaitu is committed to maintaining a technology innovation-driven approach, deepening its global collaboration network, and improving operational quality and communication with the capital market [3] - The company positions itself as a "global source of new drugs," contributing long-term value to the high-quality development of China's biopharmaceutical industry and global innovation [3]
成功纳入港股通，百奥赛图H股今天大涨22%